EKF Diagnostics (LON:EKF) Shares Up 27.3% – Still a Buy?

Shares of EKF Diagnostics Holdings plc (LON:EKF) traded up 27.3% during mid-day trading on Thursday . The company traded as high as GBX 26.90 ($0.36) and last traded at GBX 25.20 ($0.33). 2,253,335 shares traded hands during trading, an increase of 353% from the average session volume of 497,132 shares. The stock had previously closed at GBX 19.80 ($0.26).

EKF Diagnostics Price Performance

The company has a debt-to-equity ratio of 0.34, a current ratio of 4.60 and a quick ratio of 1.77. The stock’s fifty day simple moving average is GBX 21.11 and its 200-day simple moving average is GBX 23.93. The company has a market capitalization of £110.25 million, a P/E ratio of 23.08 and a beta of 0.57.

EKF Diagnostics (LON:EKF) last released its quarterly earnings results on Tuesday, March 25th. The company reported GBX 1.38 ($0.02) earnings per share (EPS) for the quarter. EKF Diagnostics had a net margin of 9.37% and a return on equity of 7.03%. On average, equities analysts forecast that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current fiscal year.

Insider Buying and Selling at EKF Diagnostics

In related news, insider Gavin T. Jones bought 50,000 shares of EKF Diagnostics stock in a transaction that occurred on Tuesday, March 25th. The stock was acquired at an average price of GBX 22 ($0.29) per share, for a total transaction of £11,000 ($14,592.73). Corporate insiders own 5.24% of the company’s stock.

About EKF Diagnostics

EKF is an AIM-listed global diagnostics business focussed on:

● Point-of-Care analysers in the key areas of Hematology and Diabetes

● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.